Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/u46tsbd2.
- Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015. The live and archived webcast will be available at http://www.veracast.com/webcasts/opco/healthcare2015/84203554236.cfm.
Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting:
- The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/o3ovz2db/lan/en.
Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
